Close Menu

Myriad

AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.

Call to Share

The Wall Street Journal reports that the American College of Medical Genetics and Genomics has called on Myriad Genetics and others to share the genetic data they have amassed.

On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.

The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.

The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.

Downgraded Variant

The Wall Street Journal reports on a family whose BRCA mutation was downgraded to a variant of uncertain significance.

The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.

A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.  

 

Pages

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.